Emideltide (DSIP) Side Effects: What Forty Years of Human Trials Actually Recorded
REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn
Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy
Citations verified against PubMed · Published: 2026-09-09 · Last updated: 2026-09-10
Emideltide is the International Nonproprietary Name for delta sleep-inducing peptide, the nine-amino-acid compound everyone in the research-peptide market calls DSIP. It is the name the FDA’s advisory committee used when it voted on the compound in July 2026, the name that appears in recent chemistry papers, and the name that will appear on any regulatory document from here on, which is why we use it. It is also one of the few research peptides with a real human safety record: synthetic DSIP was infused into volunteers and insomniacs from 1981 onward, into more than a hundred people in alcohol and opiate withdrawal, into chronic-pain patients, into women under general anaesthesia, and into diabetics as a nasal spray. This page collects every side effect and physiological change those studies recorded, explains why the endocrine claims made for it mostly failed when tested, and sets the trial record against what people injecting it today describe. Nothing here is a dose recommendation; where a study’s dose appears, it is because the study reported it.
Quick Answer: What the Emideltide Side-Effect Data Actually Shows
In the controlled human studies, emideltide was tolerated well, and that is the headline. The first human trial recorded “no psychologic, physiologic, or biochemical side effects” in six volunteers (PMID 6895513); the largest series, 107 inpatients in withdrawal, reported good tolerance “aside from headaches reported by a few patients” (PMID 6548969). The measurable effects that did show up are subtler than a side-effect list: a slight arousing effect in the first hour after injection before sleep pressure arrives (PMID 7028502); a significant increase in heart rate, fall in heart-rate variability and a paradoxical reduction of delta EEG in a 2009 anaesthesia trial (PMID 19142086); a fall in ACTH for at least three hours with cortisol unchanged (PMID 2554357); and no effect at all on growth hormone or prolactin (PMID 8475226). The trials also found a bell-shaped dose curve, where more was not more. What users report most is none of that: it is that it did nothing, followed by vivid dreams, and, in a few accounts, a night of no sleep at all.
The best-observed people ever given emideltide were six healthy volunteers in Basel in 1981, four men and two women, who received a slow morning infusion of 25 nanomoles per kilogram under double-blind, crossover conditions with continuous psychophysiological monitoring. They reported a feeling of sleep pressure almost immediately, slept 59 percent more over the next 130 minutes than after placebo, and that night fell asleep faster with better sleep efficiency. The investigators’ behavioural and EEG analyses found no sedation of the classic pharmacological kind, and no psychological, physiological or biochemical side effect.
Six middle-aged chronic insomniacs given the same dose that year slept longer with fewer interruptions and slightly more REM, with no daytime sedation or other side effects reported; the one unexpected finding was that the sleep-promoting effect did not arrive until the second hour, and in the first hour there was a slight arousing effect instead. Twenty-eight years later, twelve women receiving emideltide before and during isoflurane anaesthesia showed the other side of that coin: faster heart rates, lower heart-rate variability, and a lighter, not deeper, anaesthetic state.
Sources: PMID 6895513, PMID 7028502, PMID 19142086. When we publish an individual account here, it will be a real person, named with permission. We don’t write fiction into this slot.

Looking for Lab-Tested Peptides?
Emideltide degrades quickly in solution and reconstitutes cloudy often enough that Reddit has threads asking whether a hazy vial is normal. A batch-matched certificate of analysis with an HPLC purity result is the only way to know what is in yours. Amino Club publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.
Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.
In This Guide
- What Emideltide Is, and Why It Has Two Names
- How Emideltide Is Supposed to Work (and Why Nobody Is Sure)
- Every Human Study That Recorded Tolerability
- Headache: The Only Side Effect Named in a Large Series
- The Paradox: Alertness Before Sleep, and a Lighter Anaesthetic
- Heart Rate and Heart-Rate Variability
- Hormones: ACTH Down, Cortisol Flat, Growth Hormone Unchanged
- The Bell-Shaped Dose Curve: Why More Was Not More
- The Side Effect Nobody Lists: It Often Does Nothing
- Injection, Nasal Spray and the Bioavailability Problem
- What Users Report: Self-Reported Effects From Reddit
- Interactions That Have Actually Been Studied
- Who Was Never Studied
- Marketing Claims vs the Measured Record
- Sourcing, Reconstitution and Stability
- US Regulatory Status: The One Peptide the Committee Rejected
- Frequently Asked Questions
- Glossary of Terms
- References
What Emideltide Is, and Why It Has Two Names
Emideltide is a nonapeptide, a chain of nine amino acids, with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of about 849 daltons (PMID 8689946, PMID 6145137). It was isolated in 1977 by the Schoenenberger and Monnier group in Basel from rabbit cerebral venous blood, and named for the effect it appeared to carry: delta sleep-inducing peptide, DSIP (PMID 16539679). That name is a hypothesis about function, which is one reason the International Nonproprietary Name, emideltide, exists. INNs describe a substance, not a claim, and emideltide is the name used in the current literature (a 2020 analytical-chemistry paper uses it as a test peptide, PMID 32456912) and by the FDA’s Pharmacy Compounding Advisory Committee, which listed it as “Emideltide (DSIP)” when it voted in July 2026 (see our coverage of the vote).
Two other facts about the molecule shape everything below. First, DSIP-like immunoreactivity is found throughout the body: in the hypothalamus, in the pituitary, in gut endocrine cells, in plasma, in cerebrospinal fluid and in human breast milk, where colostrum carried around 30 ng/mL falling to about 10 ng/mL in mature milk (PMID 6547144). Second, despite half a century of work, no gene, no precursor protein and no receptor for DSIP has ever been identified. A 2006 review in the Journal of Neurochemistry titled the compound “a still unresolved riddle” and called the case for it being a sleep factor “extremely poorly documented and still weak” (PMID 16539679); a 2011 database search proposed that the immunoreactivity might come from a fragment of a histone-demethylase enzyme that differs from DSIP at two of nine positions (PMID 21262293). A compound whose natural origin is uncertain is a compound whose mechanism of side effects is also uncertain, and the honest version of this page keeps saying so.
KEY TAKEAWAY
“Emideltide” and “DSIP” are the same nine amino acids. The first is the regulatory and pharmacological name; the second is a 1977 guess about what it does. Every trial on this page studied the same molecule, so the safety record transfers between the names. If you searched for one and landed on the other, you are in the right place.
How Emideltide Is Supposed to Work (and Why Nobody Is Sure)
Three mechanisms have some human or animal support, and each predicts a different kind of side effect. The first is the hypothalamic-pituitary-adrenal axis. In two randomized, placebo-controlled studies in healthy men, a single intravenous dose of 25 nmol/kg produced a significant fall in plasma ACTH lasting at least three hours, without any change in plasma cortisol, urinary cortisol or monoamine metabolites (PMID 2554357, PMID 7698722). That is an endocrine effect in the direction sellers advertise, but, as the section on hormones explains, it did not survive a harder test. The second is the opioid system. The 1980s withdrawal trials were designed on the premise that DSIP acts as an agonist at opiate receptors, because in animals its sleep-inducing effect was reversed by naloxone (PMID 6548969); in 2018, naloxone again blocked the sleep and memory effects of a phosphorylated DSIP analogue in rats (PMID 30107169). The third is chronobiology: the Basel group interpreted its effects on narcolepsy and on a delayed-sleep-phase patient as an “accentuation of circadian and ultradian rhythms” rather than sedation (PMID 6548968), and the 1984 review recorded effects on thermoregulation, locomotor rhythms and hormone timing (PMID 6145137).
What emideltide is not, on the evidence, is a sedative. The first human study specifically reported that “sophisticated behavioral and EEG analyses revealed no sedation in the classic pharmacologic way” (PMID 6895513), and the 1983 summary of five human studies described “higher alertness and better performance” during the waking state after injection (PMID 6689058). That matters for side effects, because the things people expect from a sleep drug, next-day hangover, respiratory depression, dependence, were looked for and not found, while the things they do not expect, a wired first hour, a faster heart rate, are the ones the data contain.
Every Human Study That Recorded Tolerability
The table lists each human study we could verify on PubMed that reported on how the compound was tolerated, with the dose the investigators used. These are the doses the studies administered, not amounts we suggest; the compound’s molecular weight lets anyone convert them, and we do so once in the FAQ.
| Study | Participants | What was administered | Tolerability and physiological findings |
|---|---|---|---|
| 1981, Basel | 6 healthy volunteers, double-blind crossover | 25 nmol/kg slow IV infusion, morning | Immediate sleep pressure; sleep +59% over 130 min vs placebo; no classic sedation; “no psychologic, physiologic, or biochemical side effects” |
| 1981, Basel | 6 middle-aged chronic insomniacs | 25 nmol/kg IV, single dose | Longer, less interrupted sleep, slightly more REM; “no day-time sedation or other side effects”; slight arousing effect in the first hour, sleep effect in the second |
| 1983, Basel | Five studies, single and repeated IV, double-blind | IV; “slow injection proved essential” | “Compatibility of DSIP was good”; ~1 h latency, effects up to 20 h; higher alertness and performance when awake |
| 1983, Geneva | 67 patients in alcohol or opiate withdrawal (49 evaluable) | 25 nmol/kg IV as sole treatment | Benefit in 48 of 49; anxiety resolved more slowly than somatic signs; “No major side-effect occurred” |
| 1984, Geneva | 107 inpatients in withdrawal (47 alcohol, 60 opiate) | Repeated IV injections | Symptoms resolved or markedly improved in 87% (alcohol) and 97% (opiate) of evaluable patients; “Tolerance to the DSIP treatment was good, aside from headaches reported by a few patients” |
| 1984, Germany | 7 chronic-pain patients | IV on 5 consecutive days, then 5 injections every 48–72 h | Pain significantly lower in 6 of 7; concurrent depressive states reduced; no adverse effects described in the abstract |
| 1986, Basel | 18 chronic insomniacs, aged 29–83 | 6 × 30 nmol/kg IV over one week | Sleep normalized in both age groups; elderly took until the end of the follow-up week; no adverse effects described in the abstract |
| 1987, Basel | 14 middle-aged chronic insomniacs, placebo-controlled double-blind | 7 successive nights IV | Sleep efficiency reached normal-control levels; daytime alertness and performance significantly increased |
| 1987, Uruguay | Chronic insomniacs, double-blind crossover | 25 nmol/kg IV, four nights | Sleep changes not significant vs placebo; “of little clinical significance”; no adverse effects described |
| 1989, Sweden | 11 healthy men, randomized double-blind crossover | 25 nmol/kg IV single dose vs saline | ACTH significantly reduced for at least 3 h; plasma and urinary cortisol unaffected |
| 1992, Netherlands | 16 chronic insomniacs, double-blind parallel groups | 25 nmol/kg IV on three afternoons | Weak improvement in sleep efficiency and latency, partly attributable to the placebo group; no change in subjective sleep quality |
| 1993, Italy | 8 healthy women, aged 17–36 | 25 µg/kg IV over 30 min | No effect on growth hormone or prolactin, basal, stimulated or circadian |
| 1994, Italy | 8 normal men, aged 23–34 | 25 nmol/kg IV over 10 min | ACTH decreased; vasopressin and its responses to osmotic and postural stimuli unchanged |
| 1995, Germany | 20 healthy young men | 3 mg and 4 mg total IV infusions vs placebo | ACTH and cortisol responses to CRH and to a meal “almost identical” to placebo |
| 2014, Ukraine | 30 insulin-dependent diabetics | 300 µg intranasally daily for two months (Deltalicin) | Faster retinal recovery after photostress; no adverse effects described in the abstract |
| 2009, UK | 24 women (ASA I–II) under isoflurane anaesthesia, randomized | 25, 50 or 100 nmol/kg IV bolus, awake and anaesthetized | Heart rate significantly increased, heart-rate variability decreased, delta rhythm paradoxically reduced, burst suppression reduced, BIS increased at 25 nmol/kg: a lighter anaesthetic |
Two patterns run through the table. First, the Basel and Geneva investigators who developed the compound reported no adverse effects beyond a few headaches across everything they published, and the independent groups that failed to replicate its efficacy did not report adverse effects either; the absence of harm is consistent even where the presence of benefit is not. Second, the one modern trial with continuous cardiovascular monitoring found effects nobody in the 1980s measured. That is not a contradiction. Heart rate and heart-rate variability were simply not the endpoints of a 1981 sleep study.
Headache: The Only Side Effect Named in a Large Series
The single named adverse effect in the human literature comes from the largest series, 107 hospitalized patients treated for alcohol or opiate withdrawal with repeated intravenous injections. The investigators summarized tolerance as good “aside from headaches reported by a few patients” (PMID 6548969). The abstract gives no count and no severity, and the population was one in which headache is common for other reasons; opiate withdrawal itself produces it. The earlier Geneva series of 67 withdrawal patients, using a single 25 nmol/kg dose as the sole treatment, recorded that “no major side-effect occurred” (PMID 6328354). Headache does not appear in any of the volunteer or insomnia studies. It is the only entry on the list of classic side effects, and it is a thin one.
It is worth pausing on what that list does not contain. Across well over a hundred monitored people, the abstracts do not report nausea, dizziness, injection-site reactions, next-day grogginess, respiratory changes or withdrawal on stopping. The 1984 Kaeser trial followed seven severe insomniacs for three to seven months after a course of ten injections and found sleep still normalized in six, which is the opposite of the rebound insomnia that follows stopping a hypnotic (PMID 6391926); its only stated concern was patients with “a long-standing habit of drug addiction.” Whether the absence of these effects means they do not occur, or that 1980s abstracts did not itemize them, is a question the reader should hold open. A modern trial would have an adverse-event table; these do not.
The Paradox: Alertness Before Sleep, and a Lighter Anaesthetic
If emideltide has a signature effect that a user would notice and might call a side effect, it is this one. The 1981 insomnia study found that “sleep-promoting effects occurred only in the second hour after injection, in the first hour a slight arousing effect was indicated” (PMID 7028502). The 1983 summary put the latency of sleep induction at about one hour and the duration at up to 20 hours, and separately recorded that during the active waking state the compound “induced higher alertness and better performance” (PMID 6689058). The 1984 insomnia paper found that morning injections increased daytime activity while still improving that night’s sleep (PMID 6391925), and the 1987 placebo-controlled trial recorded significantly increased daytime alertness and mental performance after six injections (PMID 3622582). A single narcoleptic patient given repeated injections had fewer sleep attacks and more daytime alertness, with his sleep period compressed rather than lengthened (PMID 6548968).
The 2009 anaesthesia trial turned that observation into a measurement. In twelve women given emideltide before and during propofol-isoflurane anaesthesia, the compound “paradoxically, significantly reduced delta rhythm along with reducing burst suppression and increasing BIS” at the 25 nmol/kg dose; the authors concluded it “decreased (lightened) the depth of anaesthesia” (PMID 19142086). A peptide named for inducing delta sleep reduced delta EEG in anaesthetized patients. For someone injecting it before bed, the practical translation of all this is that the first hour may feel like the opposite of what they bought it for, and the Reddit record, below, contains exactly that report, including one account of a first dose followed by 38 hours awake.
RESEARCH HIGHLIGHT
Endogenous DSIP behaves the same way. In twelve healthy volunteers sampled every 30 minutes for 24 hours with polysomnography, plasma DSIP-like immunoreactivity peaked at 3 p.m., bottomed at 1 a.m., was significantly lower during REM and slow-wave sleep than when awake, tracked body temperature (r² = 0.66), and never rose before or during slow-wave sleep. The authors concluded that natural elevations “may be associated with suppression of slow wave and rapid eye movement sleep” (PMID 8175965). A second study found plasma levels fall at the moment of falling asleep, at 11 p.m. and again at 5 a.m. (PMID 8745061). Whatever the body’s own DSIP does, it does not surge to bring on deep sleep.
Heart Rate and Heart-Rate Variability
The only human study to monitor the heart continuously found that emideltide “significantly increased heart rate, decreased HRV” and altered the left-right symmetry of the EEG, in twenty-four women, half given saline, half given 25, 50 or 100 nmol/kg as an intravenous bolus first while awake and then under anaesthesia (PMID 19142086). The investigators’ interpretation was a reduction in parasympathetic tone. The size of the heart-rate change is not given in the abstract, and the bolus route is faster than the slow infusions the 1980s trials insisted on; the 1983 summary’s line that “slow injection proved essential” (PMID 6689058) is not explained in its abstract, but a bolus is the opposite of slow. Older reviews had already listed effects on heart rate and blood pressure among the compound’s animal actions (PMID 3286557). No human study has looked at blood pressure directly, and no study has looked at any of this in people with cardiovascular disease.
Heart-rate variability is also the number that consumer sleep trackers report, and it appears repeatedly in user accounts, in both directions: one poster attributes an improved HRV to switching from nasal to subcutaneous use, another reports lower deep-sleep scores. A single-night HRV reading is not a controlled measurement, but it is striking that the one physiological variable users can see is the one the controlled trial found the compound moves.
Hormones: ACTH Down, Cortisol Flat, Growth Hormone Unchanged
Emideltide is sold with a cluster of hormonal claims: that it lowers cortisol, that it boosts growth hormone during sleep, that it “normalizes” the stress axis. The human record is specific and mostly negative.
ACTH and cortisol. A single 25 nmol/kg dose reduced plasma ACTH for at least three hours in eleven men, but “plasma cortisol levels were unaffected and followed the normal diurnal decline” (PMID 2554357). The Italian study in eight men confirmed the ACTH fall (PMID 7698722). Then a German group ran the harder test: they infused 3 mg and 4 mg totals, far more than the 25 nmol/kg studies, while stimulating the axis with CRH and with a meal, and found ACTH and cortisol responses “almost identical” to placebo, concluding that their data “do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man” (PMID 7777652). The cortisol claim, in other words, has been tested in three placebo-controlled human experiments and failed in all three; the ACTH effect is real at rest and disappears under stimulation.
Growth hormone and prolactin. Eight healthy women received 25 µg/kg over 30 minutes, alone and with an arginine challenge, and three more had their overnight rhythm measured during an evening infusion: “no effects were noted” on growth hormone or prolactin under any condition (PMID 8475226). The one human dataset in which growth hormone moved is the Russian Deltaran pilot in eleven elderly diabetics, where basal and stimulated growth hormone decreased after a 60-day intranasal course (PMID 15754961). There is no human study in which emideltide raised growth hormone.
Vasopressin. Unchanged, including its responses to salt loading and standing (PMID 7698722).
What the endocrine work does show is that the body’s own DSIP-like material is tangled up with the stress axis in ways nobody has resolved: plasma levels correlate with cortisol in controls and are higher in depressed patients, who respond to CRH with a fall in DSIP where controls show a rise (PMID 2839244); patients with Cushing syndrome have lower morning DSIP, 797 versus 1,062 pmol/L, alongside less than half the normal amount of delta sleep, and the correlation between the two runs the wrong way for a causal story (PMID 7700506). None of that is a side effect of taking it. It is a warning that the hormone story sellers tell is simpler than the one the data tell.
The Bell-Shaped Dose Curve: Why More Was Not More
The 1984 review that consolidated the first decade of research described “a U-shaped activity curve for the dose as well as for the time of infusion” (PMID 6145137), and the animal pharmacology paper from the same year found “indications for bell-shaped dose-response curves of DSIP” in most experimental situations (PMID 6548967). In humans, the 1984 insomnia paper reported that repeated injections in the morning still improved night sleep, “but not so two doses daily” (PMID 6391925): doubling the frequency lost the effect. In the 2009 anaesthesia trial, the paradoxical EEG effects were reported at 25 nmol/kg, the lowest of three doses (PMID 19142086). And in rats, a 2016 study of liver stress markers found the peptide’s effects at 40 and 120 µg/kg, while “increasing the peptide dose to 360 µg/kg abolished its effects” (PMID 26902351).
For the side-effect question this cuts two ways. A compound with a bell-shaped curve does not become more dangerous in a straight line as the dose rises, which is reassuring; but it does become less predictable, and the user habit of escalating when nothing happens, well documented in the Reddit threads below, is the one strategy the pharmacology says is least likely to work. The trials that showed benefit used a single, fixed, weight-based dose and repeated it; the trials and the users who report nothing tend to have varied it.
DID YOU KNOW
In two animal models of ischaemia, DSIP and a structurally related analogue reduced heart and brain infarct size when given at reperfusion, but a pilot arm that gave the peptides during the occlusion “resulted in 100% mortality in animals” (PMID 33918965). It is a rodent finding with no human counterpart, and we include it because it is the only lethal outcome anywhere in the emideltide literature, and because it illustrates how sharply the compound’s effects can depend on timing.
The Side Effect Nobody Lists: It Often Does Nothing
The most common outcome users describe is not a side effect in the pharmacological sense, but it is the most common thing that happens, and it has trial support. The Basel group’s studies were positive, but the two independent placebo-controlled trials were not. In 1987, four nights of 25 nmol/kg in a double-blind crossover reduced awakenings and waking time, yet “no significant differences were found in comparison to baseline or to double-blind placebo nights”; slow-wave sleep and REM were unchanged, and the authors judged the improvement “of little clinical significance” (PMID 3583493). In 1992, sixteen chronic insomniacs in a matched-pairs design showed higher sleep efficiency and shorter latency on DSIP, but the effects were “weak and in part could be due to an incidental change in the placebo group,” subjective sleep quality did not move, and the conclusion was that short-term treatment “is not likely to be of major therapeutic benefit” (PMID 1299794). A 1997 review in Sleep summarized the field as “not yet clear” (PMID 9456470), and a 2003 review listed DSIP among sleep factors for which “a physiological sleep regulatory role, however, has not been determined” (PMID 12700031).
Why does this belong on a side-effects page? Because the response to a compound that does nothing is usually to take more of it, more often, or by a different route, and each of those moves is where the small amount of adverse-effect data lives: the lost effect at two doses daily, the arousal in the first hour, the nightmares users attribute to the nasal form. Our emideltide for sleep page goes through the efficacy trials in detail; the point here is that the null result is the expected result for a meaningful share of users, and the pharmacology gives no reason to think escalation changes it.
Injection, Nasal Spray and the Bioavailability Problem
Every positive human trial used slow intravenous infusion. Nobody sells that, so what the research market offers is a lyophilized vial for subcutaneous injection or a pre-mixed nasal spray, and neither route has a controlled human sleep study behind it. Three facts about the molecule bear on both. It is destroyed quickly in blood: incubation in human or rat blood released tryptophan-sized fragments in a temperature- and time-dependent way, and the authors concluded that “the rapid disappearance of injected DSIP in blood was due to degradation” (PMID 3628078). It is destroyed in cerebrospinal fluid by an aminopeptidase of about 80 kDa that also degrades enkephalins (PMID 2322270). And it does not survive the gut: in a human intestinal cell model, only 8.2 percent remained after two hours on the luminal side, and even with three protease inhibitors stabilizing 95 percent of it, none crossed to the other side (PMID 8689946). Oral emideltide is a non-starter, and any capsule sold as DSIP is selling the name.
The nasal route has more behind it than most peptide sprays, all of it from Russian-made preparations studied in Russia and Ukraine. Two 2014 papers from Odessa describe an intranasal DSIP preparation, Deltalicin or Deltalycin, given at 300 µg a day for two months to thirty insulin-dependent diabetics, half with retinopathy, in whom the recovery of visual evoked potentials after a light stress shortened from 137 to 95 seconds (PMID 25739189, PMID 25581971); an earlier pilot used a related preparation, Deltaran, in eleven elderly diabetics for 60 days and reported better sleep-quality scores alongside the growth-hormone fall noted above (PMID 15754961); and a 2001 letter reported that intranasal DSIP increased the P300 evoked potential (PMID 11763019). In rats, eight days of intranasal DSIP at 120 µg/kg after a stroke sped motor recovery without significantly shrinking the infarct (PMID 34500605). None of these abstracts describes adverse effects, and none is a sleep trial. Our DSIP nasal spray page covers what the sprays on the market contain and the molecular-weight argument for and against nasal absorption of an 849-dalton peptide.
What Users Report: Self-Reported Effects From Reddit
We searched Reddit on September 9, 2026 for DSIP, emideltide and delta sleep-inducing peptide, screened 488 posts, read the full comment threads of 24 and the posts of a further dozen, across r/Peptides, r/Peptidesource, r/Biohackers, r/Biohacking, r/BodyHackGuide, r/BiohackingU, r/sleep, r/sleephackers, r/USPeptides and r/PeptideForum, dated 2021 to September 2026. Everything below is paraphrased and linked, uses no usernames, describes products nobody verified, and reports amounts only as the posters described them. Most posters were also using other compounds, often a GLP-1 drug or a growth-hormone secretagogue, so nothing here isolates emideltide.
The most common report is no effect. A poster who tried DSIP “several times” with varying amounts and timing, all subcutaneous and from a source they trusted, called it disappointing and got nothing (r/Peptides). Another, asking what peptide had improved anyone’s sleep, wrote that DSIP and pinealon had both had zero effect injected subcutaneously (r/Biohacking). A third, waking at 3 a.m. every night, had tried epitalon and DSIP and found neither helped (r/Biohacking). A long-time user described it as hit or miss and blamed mismatched expectations about what it is supposed to do (r/BodyHackGuide). An article-style post in a performance sub was titled around “who it does nothing for” (r/NTNPerformance).
Paradoxical wakefulness. The clearest adverse report in the set: a first-time user took what they described as 200 mcg an hour before bed, had what they called an adverse reaction, and did not sleep for the next 38 hours; in the same thread, one reply described four nights of worse or nonexistent sleep and another said their sleep “suffered immensely” while on it and recovered once they stopped (r/Peptidesource). Elsewhere a user wrote that all it did was give them insomnia (r/Peptides); a first-day user at what they called about 200 mcg felt more alert than usual and barely slept (r/USPeptides); a 31-year-old with sleep-maintenance insomnia slept about four hours on it and noted the one upside was not being tired the next day (r/Biohackers); one poster found it worked for the first few weeks and then began waking wide awake in the middle of the night (r/BiohackingU); and the poster who eventually called it transformative had a harder time falling asleep for the first three weeks (r/BodyHackGuide). This is the user-scale version of the first-hour arousal the 1981 trial recorded, the daytime alertness four trials reported and the lightened anaesthesia the 2009 trial measured, and it is the report that most deserves to be on a side-effects page.
Next-day effects, head pressure and dreams that wake you. Grogginess is rare in the threads but not absent: one user felt tired for many hours the following day on each of a few tries (r/BiohackingU), and another summarized their experience as wild dreams, a little grogginess and little change in the metrics (r/Biohacking). In that thread a regular user described a pressure in the head five to ten minutes after injecting, which they distinguished from a headache and said passed into relaxation; it is the closest user counterpart to the headaches in the 1984 withdrawal series. One poster’s dreams became so loud they woke five or more times a night and gave up (r/Peptides); another found deep sleep concentrated in the first half of the night with none in the second, and a reply reported more deep sleep but much less REM and a worse mood the next day (r/Peptides). A single poster reported acne on the back and face while using it (r/BiohackingU).
The effect fades, and users describe the bell curve themselves. Several long-term users say the effect wears off after four or five nights and that they cycle off (r/Peptides), that tolerance builds fast (r/Peptides), or that the improvement lasted about a week (r/Peptides). One wrote that a higher amount and daily use both took the effect away and that two or three nights a week worked best (r/Peptides); a nasal-spray user found doubling the sprays did nothing or disrupted the pattern (r/BodyHackGuide); another tried everything from what they called 50 to 500 mcg and had it work once in twenty attempts (r/BodyHackGuide). Without knowing it, these users are describing the U-shaped dose curve of the 1984 review and the failed twice-daily schedule of the 1984 insomnia paper.
Vivid dreams, nightmares and lucid dreams. One poster found the nasal form gave them “such nightmares” that they switched to subcutaneous use at a lower amount, after which sleep improved and their tracker’s HRV rose (r/Peptides). Another titled a review around the “Inception-level lucid dreams” it produced (r/USPeptides). The trials recorded slightly more REM in insomniacs and enhanced REM in the narcolepsy case (PMID 7028502, PMID 6548968), which is at least consistent with more dream recall, though no trial asked about dreams.
Tracker-measured deep and REM sleep, and the mismatch. Several posters report the effect they hoped for, and they report it in the language of consumer sleep trackers. Others report the reverse mismatch: feeling knocked out while their band showed no more deep or REM sleep than usual (r/Biohackers), a watch showing the same 45 minutes of delta sleep with or without it while the dreams got more interesting, or feeling well rested with no bump on the ring (r/Biohacking). The positive tracker reports: deep and REM sleep up by about 40 minutes each on the first night (r/Peptides); the highest deep and REM figures a poster had ever recorded by night four, with the caveat that tracker accuracy is uncertain (r/Peptides); a “huge improvement” after increasing from what they described as 300 to 400 mcg (r/sleep); and a first night that “looks promising” (r/Peptides). One poster with mild sleep apnea wrote that DSIP had “basically fixed” it for a month (r/sleephackers); another reported it transformed their sleep but only after they nearly quit early, and urged patience (r/BodyHackGuide). A poster with three to five hours of sleep a night after alcohol withdrawal credited adding DSIP with the improvement (r/BodyHackGuide), which is the one user report that lines up with an actual indication in the trials.
Escalation. The threads document exactly the behaviour the bell-shaped curve argues against: users who felt nothing describe raising the amount, from what they call 100 to 300 to 400 to 500 mcg, and changing timing and route (r/Peptides, r/sleep, r/BiohackingU). Whether the ones who eventually reported an effect got it from the higher amount or from the passage of nights is not something a self-report can separate.
Product integrity and legality. A poster asked whether a reconstituted DSIP vial that was “less clear” than their other peptides was safe (r/Peptidesource); another posted a photo of a freshly reconstituted vial asking the same (r/Peptides). An Australian poster received a letter that their DSIP shipment had been seized and the Therapeutic Goods Administration was involved (r/Peptides). A poster whose testosterone clinic had started offering DSIP was on a prescription benzodiazepine they wanted to stop, which is the 1987 delayed-sleep-phase case report playing out in a clinic rather than a sleep lab (r/PeptideForum, PMID 3582201).
The 1983 indication, unsupervised. A striking number of users are doing at home what the Geneva trials did in hospital. One used it while coming off buprenorphine (r/Peptides); another, two years into a methadone taper with sleep “destroyed,” had read the withdrawal trials and was trying it (r/USPeptides); a third reported that since starting it they had stopped the alprazolam and clonazepam they had been overusing for sleep (r/Biohackers); and a September 2026 post asks specifically about using it on Suboxone or Sublocade because the poster knew it “interacts with opioid receptors” (r/Peptides). The trials that support this use were open, uncontrolled and intravenous, and the one thing every investigator in them had that these users do not is a ward.
Confounded successes. A 27-year-old attributed coming off blood-pressure medication and losing 28 pounds to a retatrutide-plus-DSIP stack (r/Biohackers); retatrutide alone accounts for both outcomes in its phase 3 trials, and nothing in the post separates the two compounds. Several posters on GLP-1 drugs added DSIP because those drugs disturbed their sleep (r/BodyHackGuide), which makes the GLP-1 the likelier cause of whatever changed.
What this is and is not: a map of what people say happens, weighted toward those who had something to say, and toward people who owned a sleep tracker. It is not a rate, not a comparison to placebo, and not a verification of what was in anyone’s vial. The absence of headache reports, the one trial-documented side effect, and the presence of dream and wakefulness reports, which no trial itemized, is the kind of gap that appears when one set of observers is measuring and the other is living it.
Interactions That Have Actually Been Studied
Almost nothing, in humans. The interactions with a human data point are with anaesthetic agents, where emideltide lightened propofol-isoflurane anaesthesia and raised heart rate (PMID 19142086); with CRH, where its ACTH-lowering effect vanished under CRH stimulation (PMID 7777652); with arginine, where it did not alter the growth-hormone response (PMID 8475226); and with lithium, which raised cerebrospinal-fluid DSIP in patients with affective illness, according to the title of a 1988 report whose abstract is not indexed (PMID 3370272). In animals, naloxone reverses its sleep and memory effects (PMID 30107169), it abolished the sleep-suppressing effect of morphine in cats and reduced naloxone-induced withdrawal jumping in morphine-dependent mice (PMID 6548967), and chronic alcohol lowered brain DSIP in rats while a single dose raised it (PMID 6897366). The human withdrawal trials are themselves an interaction study of a kind: the compound was given to people with alcohol or opiates leaving their systems, and tolerated (PMID 6328354, PMID 6548969).
What has never been studied is the combination users actually run. There is no data on emideltide with GLP-1 receptor agonists, with growth-hormone secretagogues, with melatonin, with benzodiazepines or z-drugs, with antidepressants, or with the pinealon and epitalon it is sold alongside in “sleep stacks.” The opioid-system findings are the one place a reader might reasonably pause: a compound whose effects are blocked by naloxone in animals, given to someone on buprenorphine, is an experiment nobody has run, and a September 2026 thread asking about peptides for people on Suboxone or Sublocade shows the question is live (r/Peptides).
Who Was Never Studied
The human record spans healthy young men, healthy young women, middle-aged and elderly insomniacs, people in withdrawal, chronic-pain patients, women having elective surgery and elderly diabetics. It does not include pregnant or breastfeeding women, although DSIP-like material is a natural constituent of breast milk (PMID 6547144); children, although Russian reports of a paediatric product exist outside the indexed literature; anyone with heart disease, although the one cardiovascular finding is a rise in heart rate; anyone with a seizure disorder, although Russian animal work describes DSIP as both anticonvulsant and, at central doses, capable of provoking “epileptic, parkinsonian, withdrawal, rotational and other syndromes” (PMID 8581045, PMID 19102071); or anyone with major depression, where the endogenous peptide is measurably abnormal (PMID 2859636, PMID 9606527). The 1984 Kaeser trial’s caution about patients with a history of drug addiction is the only population-level warning any investigator issued (PMID 6391926). None of these gaps is evidence of harm. Each is evidence of no evidence, which for a compound that lowers ACTH and raises heart rate is not the same as reassurance.
Marketing Claims vs the Measured Record
Vendor and clinic pages for DSIP tend to make the same six claims. Here is each one set against the human data.
| Claim | What the human studies found | Source |
|---|---|---|
| “Increases deep (delta) sleep” | Better sleep efficiency and less stage 1 in the Basel trials; slow-wave sleep unchanged in the 1987 independent trial; delta EEG reduced under anaesthesia | 6895513, 3583493, 19142086 |
| “Lowers cortisol” | Cortisol unchanged in all three placebo-controlled tests; ACTH fell at rest but not under CRH or meal stimulation | 2554357, 7777652 |
| “Boosts growth hormone” | No effect on GH or prolactin in eight women; GH decreased in the elderly-diabetic intranasal pilot | 8475226, 15754961 |
| “Non-sedating, no hangover” | Supported: no classic sedation, no daytime sedation, higher daytime alertness reported in four studies | 6895513, 3622582 |
| “Helps with withdrawal and pain” | Open, uncontrolled series in the 1980s reported benefit in most withdrawal patients and 6 of 7 pain patients; never replicated in a controlled design | 6548969, 6548970 |
| “Works as a nasal spray” | Human intranasal data exist only from Ukrainian and Russian diabetic-retinopathy and elderly-diabetic pilots, none of them sleep trials; no adverse effects described | 25739189, 15754961 |
PERSONAL OBSERVATION — PI EDITORIAL
Emideltide is unusual among the compounds we cover in that the marketing is less accurate than the 1981 papers were. The Basel group never claimed it lowered cortisol or raised growth hormone; they claimed it normalized disturbed sleep without sedating, and their own data on alertness in the first hour is right there in the abstracts. The cortisol and growth-hormone language was added later by people selling it, and it fails the human tests that were run specifically to check it. When a listing tells you what a compound does to your hormones, the question to ask is which of the four placebo-controlled endocrine studies it is citing. None of them supports the sentence.
Sourcing, Reconstitution and Stability
Emideltide is sold lyophilized, most often in vials labelled 5 mg, and as pre-mixed nasal sprays. The degradation data above is the reason stability matters more for this peptide than for most: a compound that blood and CSF enzymes clear rapidly, and that loses its N-terminal tryptophan as the first metabolic step (PMID 3777433), is a compound whose reconstituted solution should be treated as perishable, and a pre-mixed aqueous spray as more perishable still. Two of the Reddit threads we read were people asking whether a hazy reconstituted vial was normal; we cannot tell them, and neither can anyone else without a certificate of analysis for that batch. The minimum for any vial considered is a batch-matched COA with an HPLC purity result and, ideally, a mass-spectrometry identity confirmation, as explained in our guide to reading a COA. Our vendor scores cover which research vendors publish testing at all. For converting a vial’s contents into syringe units after reconstitution, our peptide calculator does the arithmetic; it does not suggest an amount, and neither do we.
US Regulatory Status: The One Peptide the Committee Rejected
Emideltide is not an approved drug anywhere we can find, and in the United States it has just become the clearest example of a research peptide that regulators looked at and declined. At the FDA’s Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026, seven peptides were considered for the 503A bulk drug substances list, which would have allowed licensed compounding pharmacies to prepare them on prescription. BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon were recommended. “Emideltide (DSIP)”, considered for opioid withdrawal, chronic insomnia and narcolepsy, lost the vote 6 to 7 with one abstention, the single rejection of the meeting (see our full coverage of the vote). The practical consequence is that emideltide cannot be legally compounded for patients in the US, and remains available only as a research chemical labelled for non-human use. The Australian poster whose shipment was seized (r/Peptides) is a reminder that other jurisdictions enforce that status at the border.
The committee’s indications list is itself worth noticing. Opioid withdrawal, chronic insomnia and narcolepsy are precisely the three uses the 1983–1987 human studies on this page investigated. The committee was looking at the same forty-year-old evidence we are, and half of it found the evidence insufficient.
Frequently Asked Questions
Is emideltide the same thing as DSIP?
Yes. Emideltide is the International Nonproprietary Name; DSIP, delta sleep-inducing peptide, is the 1977 descriptive name. Both refer to the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. The FDA’s advisory committee and recent chemistry papers use emideltide; vendors and users use DSIP.
What side effects did the human trials of emideltide report?
Very few. The first volunteer study reported no psychological, physiological or biochemical side effects; the insomnia trials reported no daytime sedation; the largest series, 107 withdrawal patients, reported good tolerance apart from headaches in a few. The measurable changes were a slight arousing effect in the first hour, a fall in ACTH with cortisol unchanged, and, in a 2009 anaesthesia trial, increased heart rate, decreased heart-rate variability and a lighter anaesthetic.
Can emideltide cause insomnia or keep you awake?
The trials found a slight arousing effect in the first hour after injection before sleep pressure arrived, and higher daytime alertness after morning injections. One Reddit user described being unable to sleep for 38 hours after a first dose. A wired first hour is the most plausible acute effect a user would notice.
Does emideltide lower cortisol?
Not in any placebo-controlled human study. A single dose lowered ACTH for about three hours while cortisol followed its normal decline; a larger infusion had no effect on ACTH or cortisol responses to CRH or to a meal. The investigators concluded their data did not support an inhibitory role on cortisol in man.
Does emideltide increase growth hormone?
No human study has shown that. Eight healthy women showed no change in growth hormone or prolactin, basal or stimulated, and an intranasal pilot in elderly diabetics recorded a decrease in growth hormone after 60 days.
Does emideltide cause vivid dreams or nightmares?
No trial asked. The insomnia trials recorded slightly more REM sleep, and users report vivid or lucid dreams and, with the nasal form in one account, nightmares. It is the most common user-reported effect after “nothing.”
Is emideltide addictive or does it cause rebound insomnia?
The only long follow-up, three to seven months after a ten-injection course in seven insomniacs, found sleep still normalized in six, the opposite of rebound. No study reported dependence. The trial’s one caution concerned patients with an existing history of drug addiction.
How much emideltide did the trials use?
Most used 25 nmol/kg by slow intravenous infusion; one used 30 nmol/kg. At a molecular weight of 849, 25 nmol/kg is about 21 µg/kg, roughly 1.5 mg for a 70 kg adult, given intravenously and slowly. The intranasal Ukrainian studies used 300 µg a day. These are the doses the studies reported, given by routes and under monitoring that no research-market use reproduces; they are not recommendations.
Why did the FDA committee reject emideltide?
The July 2026 Pharmacy Compounding Advisory Committee vote on adding it to the 503A bulks list for opioid withdrawal, chronic insomnia and narcolepsy failed 6 to 7 with one abstention. The evidence for those indications is the small, mostly uncontrolled 1980s literature summarized on this page; two independent placebo-controlled trials found little or no effect.
Is emideltide safe to take with other peptides or medications?
Unknown. The only human interaction data involve anaesthetic agents (lighter anaesthesia, faster heart rate), CRH, arginine and lithium. There is no study of emideltide with GLP-1 drugs, growth-hormone secretagogues, melatonin, sedatives or antidepressants. In animals its effects are blocked by naloxone, which makes combination with opioid medications an untested question.
Does emideltide work as a nasal spray?
The only human intranasal data come from Ukrainian and Russian pilots in diabetic patients, which reported retinal and cognitive measures, not sleep, and described no adverse effects. No controlled human sleep study of nasal emideltide exists. It does not survive the digestive tract, so oral forms cannot deliver the intact peptide.
Glossary of Terms
- Emideltide: the International Nonproprietary Name for delta sleep-inducing peptide (DSIP), a nine-amino-acid peptide isolated in 1977.
- INN: International Nonproprietary Name; the generic, claim-free name assigned to a pharmaceutical substance, used by regulators worldwide.
- Nonapeptide: a peptide of nine amino acids.
- Delta sleep / slow-wave sleep: the deepest stage of non-REM sleep, defined by slow, high-amplitude EEG waves; the effect DSIP was named for and the one the independent trials failed to find.
- ACTH: adrenocorticotropic hormone, the pituitary signal that drives cortisol release; lowered by emideltide at rest, but not under stimulation.
- Heart-rate variability (HRV): the beat-to-beat variation in heart rate, a marker of autonomic balance; decreased by emideltide in the one trial that measured it, and the number consumer sleep trackers report.
- BIS (bispectral index): an EEG-derived score of anaesthetic depth; emideltide raised it, meaning lighter anaesthesia.
- Bell-shaped (U-shaped) dose curve: a dose-response relationship in which the effect peaks at an intermediate dose and falls at higher ones; documented for DSIP in animals and suggested in humans.
- nmol/kg: nanomoles per kilogram of body weight, the weight-based unit the trials used; convertible to micrograms using the molecular weight.
- 503A bulks list: the FDA list of substances that licensed pharmacies may compound on prescription; emideltide was voted down for it in July 2026.
- Deltaran / Deltalicin: Russian-made pharmaceutical preparations of DSIP, given intranasally in the only human nasal studies indexed on PubMed (Russia and Ukraine).
References
- Schneider-Helmert D, Gnirss F, Monnier M, et al. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981. PMID 6895513
- Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981. PMID 7028502
- Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983. PMID 6689058
- Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. 1983. PMID 6328354
- Dick P, Costa C, Fayolle K, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984. PMID 6548969
- Larbig W, Gerber WD, Kluck M, et al. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984. PMID 6548970
- Schneider-Helmert D. DSIP in insomnia. Eur Neurol. 1984. PMID 6391925
- Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984. PMID 6391926
- Schneider-Helmert D. Effects of DSIP on narcolepsy. Eur Neurol. 1984. PMID 6548968
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. PMID 6145137
- Scherschlicht R, Aeppli L, Polc P, et al. Some pharmacological effects of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984. PMID 6548967
- Graf MV, Hunter CA, Kastin AJ. Presence of delta-sleep-inducing peptide-like material in human milk. J Clin Endocrinol Metab. 1984. PMID 6547144
- Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1986. PMID 3792404
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987. PMID 3622582
- Monti JM, Debellis J, Alterwain P, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987. PMID 3583493
- Schneider-Helmert D, Hermann E, Schoenenberger GA. [The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia]. Dtsch Med Wochenschr. 1987. PMID 3582201
- Graf MV, Saegesser B, Schoenenberger GA. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987. PMID 3628078
- Graf MV, Saegesser B, Schoenenberger GA. Separation of tryptophan from DSIP, a Trp-nonapeptide, by adsorption to aluminum oxide. Anal Biochem. 1986. PMID 3777433
- Yehuda S, Carasso RL. DSIP—a tool for investigating the sleep onset mechanism: a review. Int J Neurosci. 1988. PMID 3286557
- Lesch KP, Widerlöv E, Ekman R, et al. Delta sleep-inducing peptide response to human corticotropin-releasing hormone (CRH) in major depressive disorder. Biol Psychiatry. 1988. PMID 2839244
- Regnéll G, Widerlöv E, Ekman R. Delta sleep-inducing peptide in CSF of patients with affective illness is elevated by lithium treatment. Biol Psychiatry. 1988. PMID 3370272
- Bjartell A, Ekman R, Bergquist S, et al. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989. PMID 2554357
- Nyberg F, Thörnwall M, Hetta J. Aminopeptidase in human CSF which degrades delta-sleep inducing peptide (DSIP). Biochem Biophys Res Commun. 1990. PMID 2322270
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992. PMID 1299794
- Giusti M, Carraro A, Porcella E, et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993. PMID 8475226
- Chiodera P, Volpi R, Capretti L, et al. Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Horm Res. 1994. PMID 7698722
- Friedman TC, Garcia-Borreguero D, Hardwick D, et al. Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep. J Clin Endocrinol Metab. 1994. PMID 8175965
- Friedman TC, García-Borreguero D, Hardwick D, et al. Decreased delta-sleep and plasma delta-sleep-inducing peptide in patients with Cushing syndrome. Neuroendocrinology. 1994. PMID 7700506
- Späth-Schwalbe E, Schäfer A, Uthgenannt D, et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995. PMID 7777652
- Seifritz E, Müller MJ, Schönenberger GA, et al. Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides. 1995. PMID 8745061
- Augustijns PF, Borchardt RT. Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. Drug Metab Dispos. 1995. PMID 8689946
- Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997. PMID 9456470
- Hruz P, Zechner S, Heimberg D, et al. Intranasal administration of delta sleep-inducing peptide increases P300. J Clin Psychopharmacol. 2001. PMID 11763019
- Obál F Jr, Krueger JM. Biochemical regulation of non-rapid-eye-movement sleep. Front Biosci. 2003. PMID 12700031
- Odin VI, Belikova TV, Pushkova ES, et al. [Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide]. Adv Gerontol. 2004. PMID 15754961
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID 16539679
- Pomfrett CJ, Dolling S, Anders NR, et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009. PMID 19142086
- Mikhaleva II, Prudchenko IA, Ivanov VT. JmjC-domain-containing histone demethylases of the JMJD1B type as putative precursors of endogenous DSIP. Peptides. 2011. PMID 21262293
- Kresiun NV, Godlevskii LS. [Using deltalicin for the treatment of patients with diabetic retinopathy]. Eksp Klin Farmakol. 2014. PMID 25739189
- Kresyun NV. The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy. Rev Med Chir Soc Med Nat Iasi. 2014. PMID 25581971
- Bobyntsev II, Kryukov AA, Belykh AE, et al. Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress. Bull Exp Biol Med. 2016. PMID 26902351
- Roy K, Chauhan G, Kumari P, et al. Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude. Life Sci. 2018. PMID 30107169
- Cui L, Ma Y, Li M, et al. An acidic residue reactive and disulfide bond-containing cleavable cross-linker for probing protein 3D structures based on electrochemical mass spectrometry. Talanta. 2020. PMID 32456912
- Tukhovskaya EA, Shaykhutdinova ER, Ismailova AM, et al. DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion. Biomedicines. 2021. PMID 33918965
- Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021. PMID 34500605
- Shandra AA, Godlevskii LS, Vast’ianov RS, et al. [The role of the delta sleep-inducing peptide in the formation of neuropathological syndromes]. Fiziol Zh Im I M Sechenova. 1995. PMID 8581045
- Stanojlović O, Hrnčić D, Radosavljević T, et al. [Endogenous anticonvulsants: neuropeptide Y and delta sleep inducing peptide]. Med Pregl. 2008. PMID 19102071
- Lindström LH, Ekman R, Walleus H, et al. Delta-sleep inducing peptide in cerebrospinal fluid from schizophrenics, depressives and healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 1985. PMID 2859636
- Westrin A, Ekman R, Träskman-Bendz L. High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. Biol Psychiatry. 1998. PMID 9606527
- Burov IuV, Iukhananov RIu, Maiskii AI, et al. [Level of delta sleep-inducing peptide (DSIP) in the brain of rats with different alcoholic motivation]. Biull Eksp Biol Med. 1982. PMID 6897366
- Peptide Insider. FDA Peptide Vote 2026: What the Committee Decided. August 4, 2026. peptideinsider.org
- Reddit threads cited inline were read on September 9, 2026; the search and thread log is kept in our editorial records.